Overexpression of SLC3A1 enhances tumor progression in breast cancer cells, while blocking SLC3A1 with specific siRNA or SLC3A1-specific inhibitor sulfasaliazine inhibits tumor growth (99). Here, SLC3A1 is linked to breast carcinoma.